title: Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative.
authors.affiliation: CKD Research Institute, CKD Pharmaceutical Corporation, Seoul 152-600, Korea.
authors.forename: J H
authors.initials: JH
authors.lastname: Lee
authors.forename: J M
authors.initials: JM
authors.lastname: Lee
authors.forename: K H
authors.initials: KH
authors.lastname: Lim
authors.forename: J K
authors.initials: JK
authors.lastname: Kim
authors.forename: S K
authors.initials: SK
authors.lastname: Ahn
authors.forename: Y J
authors.initials: YJ
authors.lastname: Bang
authors.forename: C I
authors.initials: CI
authors.lastname: Hong
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000494:pharmacology*; D002166:Camptothecin / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D059004:Topoisomerase I Inhibitors; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D059004:Topoisomerase I Inhibitors; C116963:belotecan; D002166:Camptothecin